Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Management of Invasive Pulmonary Aspergillosis in Intensive Care Units: Guidelines From the Fungal Infection Network of Switzerland (FUNGINOS).Mycoses · 2025
   Guideline
2. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.The Lancet. Infectious diseases · 2019
   Guideline
3. Real World Posaconazole Pharmacokinetic Data in Paediatric Stem Cell Transplant Recipients.Children (Basel, Switzerland) · 2025
   Article
4. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).The Journal of antimicrobial chemotherapy · 2023
   Review
5. Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation.Clinical pharmacokinetics · 2023
   Review
6. What Is New in Pulmonary Mucormycosis?Journal of fungi (Basel, Switzerland) · 2023
   Review
7. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.Pharmaceutics · 2022
   Article
8. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position PaperIntensive care medicine · 2020
   Review
9. Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension.Antimicrobial agents and chemotherapy · 2019
   Article
10. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.British journal of clinical pharmacology · 2018
    Article
11. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.Antimicrobial agents and chemotherapy · 2017
    Article
12. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Annals of hematology · 2016
    Article

Corrections and comments

• Erratum for
  Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.2016

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.